AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...

Calquence (acalabrutinib) is a brand-name oral tablet that’s prescribed for certain types of cancer in adults. As with other drugs, Calquence can cause side effects, such as low levels of blood ...

CALQUENCE plus venetoclax with obinutuzumab reduced the risk of disease progression or death by 58% versus standard of care in this setting. CALQUENCE plus venetoclax poised to become first all ...

Calquence may reactivate the hepatitis B virus in people who already have this virus in their bodies. With reactivation, the virus becomes active again and causes symptoms.

Calquence is taken twice a day, about 12 hours between each dose, with or without food. Calquence comes in tablets and capsules. Do not open, crush, chew, or break the tablets and capsules.

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’ s CALQUENCE ® in combination with venetoclax, with or without ...

Based on ECHO Phase III trial which demonstrated CALQUENCE combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.

If Calquence requires prior authorization and you don’t receive it before you start treatment, you could pay the full cost of the drug. Be sure to ask your insurance company whether Calquence ...

Calquence (acalabrutinib) has potential interactions with other medications and some supplements. For example, Calquence can interact with ketoconazole and carbamazepine. Calquence is a ...

CALQUENCE plus venetoclax with obinutuzumab demonstrated a 58% reduction in the risk of disease progression or death compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0 ...